Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Clinical trial NCT06609304 · RECRUITING

Trial details

NCT number: NCT06609304
Sponsor: Zhengzhou University
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Lymphoma, B-Cell

Start date: 2024-09-30
Primary completion: 2026-08-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.